Partnering with Patients to Improve Therapeutic Outcomes: Incretin-Based Therapy for Type 2 Diabetes

References

• . Centers for Disease Control and Prevention. 2007 National Diabetes Fact Sheet. Atlanta, GA: CDC; 2007
   Google Scholar
• . Nauck M, Frid A, Hermansen K, ; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90
   PubMed Web of Science ®Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–986
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB, ; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . ; Action to Control Cardiovascular Risk in Diabetes Study GroupGerstein HC, Miller ME, Byington RP, . Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559
   PubMed Web of Science ®Google Scholar
• . ; ADVANCE Collaborative GroupPatel A, MacMahon S, Chalmers J, . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572
   PubMed Web of Science ®Google Scholar
• . Duckworth W, Abraira C, Moritz T, ; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139
   PubMed Web of Science ®Google Scholar
• . Skyler JS, Bergenstal R, Bonow RO, ; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol. 2009;53(3):298–304
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention. Rates of risk factors for complications, 2009. Atlanta, GA: CDC; 2009
   Google Scholar
• . Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782–787
   PubMed Web of Science ®Google Scholar
• . Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med. 2006;12(1):62–66
   PubMed Web of Science ®Google Scholar
• . Wing SS. The UPS in diabetes and obesity. BMC Biochem. 2008;9 ( suppl 1):S6
   PubMed Web of Science ®Google Scholar
• . Zinman B. Type 2 diabetes mellitus: magnitude of the problem and failure to achieve glycemic control. Endocrinol Metab Clin North Am. 2006;35( suppl 1):3–5
   PubMed Web of Science ®Google Scholar
• . Montecucco F, Steffens S, Mach F. Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators Inflamm. 2008;2008:767623
   PubMed Web of Science ®Google Scholar
• . ; Look AHEAD Research GroupPi-Sunyer X, Blackburn G, Brancati FL, . Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374–1383
   PubMed Web of Science ®Google Scholar
• . United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310(6972):83–88
   PubMed Web of Science ®Google Scholar
• . Aucott L, Rothnie H, McIntyre L, Thapa M, Waweru C, Gray D. Long-term weight loss from lifestyle intervention benefits blood pressure?: a systematic review. Hypertension. 2009;54(4):756–762
   PubMed Web of Science ®Google Scholar
• . Khaodhiar L, Cummings S, Apovian CM. Treating diabetes and prediabetes by focusing on obesity management. Curr Diab Rep. 2009;9(5):348–354
   PubMed Web of Science ®Google Scholar
• . Layman DK, Evans EM, Erickson D, . A moderate-protein diet produces sustained weight loss and long-term changes in body composition and blood lipids in obese adults. J Nutr. 2009;139(3):514–521
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association Standards of Medical Care − 2009. Diabetes Care. 2007;32:S13–S61
   Web of Science ®Google Scholar
• . Rodbard HW, Blonde L, Braithwaite SS, ; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13( suppl 1):1–68
   PubMedGoogle Scholar
• . Kruger J, Yore MM, Kohl HW 3rd. Leisure-time physical activity patterns by weight control status: 1999-2002 NHANES. Med Sci Sports Exerc. 2007;39(5):788–795
   PubMed Web of Science ®Google Scholar
• . Sheehan MT. Current therapeutic options in type 2 diabetes mellitus: a practical approach. Clin Med Res. 2003;1(3):189–200
   PubMedGoogle Scholar
• . Ferrannini E, Fonseca V, Zinman B, . Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11(2):157–166
   PubMed Web of Science ®Google Scholar
• . Barnett A, Allsworth J, Jameson K, Mann R. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. Curr Med Res Opin. 2007;23(7):1493–1507
   PubMed Web of Science ®Google Scholar
• . Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106–1118
   PubMed Web of Science ®Google Scholar
• . Grey A, Bolland M, Gamble G, . The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007;92(4):1305–1310
   PubMed Web of Science ®Google Scholar
• . Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168(8):820–825
   PubMed Web of Science ®Google Scholar
• . Schwartz AV, Sellmeyer DE, Vittinghoff E, . Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91(9):3349–3354
   PubMed Web of Science ®Google Scholar
• . Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care. 2007;30(6):1574–1576
   PubMed Web of Science ®Google Scholar
• . Home PD, Pocock SJ, Beck-Nielsen H, . Rosiglitazone evaluated for cardiovascular outcomes–an interim analysis. N Engl J Med. 2007;357(1):28–38
   PubMed Web of Science ®Google Scholar
• . Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180–1188
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB, . Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008;31(1):173–175
   PubMed Web of Science ®Google Scholar
• . Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28(10):1569–1581
   PubMed Web of Science ®Google Scholar
• . Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9(5):648–659
   PubMed Web of Science ®Google Scholar
• . Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007;9(3):418–427
   PubMed Web of Science ®Google Scholar
• . Pfutzner A, Reimer T, Hohberg C, Frokjaer LP, Jorgensen C. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin. 2008;24(9):2545–2549
   PubMed Web of Science ®Google Scholar
• . Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther. 2004;26(9):1498–1505
   PubMed Web of Science ®Google Scholar
• . Davis EM, Christensen CM, Nystrom KK, Foral PA, Destache C. Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization. Am J Health Syst Pharm. 2008;65(14):1347–1357
   PubMed Web of Science ®Google Scholar
• . McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients' perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. Diabetes Technol Ther. 2009;11(3):195–201
   PubMed Web of Science ®Google Scholar
• . Boule NG, Haddad E, Kenny GP, Wells GA, Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA. 2001;286(10):1218–1227
   PubMed Web of Science ®Google Scholar
• . Kahn SE, Haffner SM, Heise MA, . Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443
   PubMed Web of Science ®Google Scholar
• . Cook MN, Girman CJ, Stein PP, Alexander CM, Holman RR. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care. 2005;28(5):995–1000
   PubMed Web of Science ®Google Scholar
• . Aschner P, LaSalle J, McGill M. The team approach to diabetes management: partnering with patients. Int J Clin Pract Suppl. 2007(157):22–30
   Google Scholar
• . Austin MM. Diabetes educators: partners in diabetes care and management. Endocr Pract. 2006;12( suppl 1):138–141
   PubMedGoogle Scholar
• . Joseph JA, Underwood A, Nadeau D. The Color Code: A Revolutionary Eating Plan for Optimum Health. New York, NY: Hyperion; 2003
   Google Scholar
• . Hamdy O, Carver C. The Why WAIT program: improving clinical outcomes through weight management in type 2 diabetes. Curr Diab Rep. 2008;8(5):413–420
   PubMed Web of Science ®Google Scholar
• . West DS, DiLillo V, Bursac Z, Gore SA, Greene PG. Motivational interviewing improves weight loss in women with type 2 diabetes. Diabetes Care. 2007;30(5):1081–1087
   PubMed Web of Science ®Google Scholar
• . Unger J, Nadeau DA. Defining the role of incretin mimetic therapy in the management of type 2 diabetes. J Fam Pract. 2007;56( 12 suppl new):S4–S10
   Google Scholar
• . Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 1999;22(7):1137–1143
   PubMed Web of Science ®Google Scholar
• . Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359(9309):824–830
   PubMed Web of Science ®Google Scholar
• . Strauss A, Moskalenko V, Chodnevskaja I, . Exendin-4 improves the oral glucose tolerance in diabetic rats: pancreas regeneration, better function of pancreatic islets, or impaired glucose uptake? Transplant Proc. 2008;40(2):533–535
   PubMed Web of Science ®Google Scholar
• . Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care. 2007;30(8):2032–2033
   PubMed Web of Science ®Google Scholar
• . Vilsboll T, Zdravkovic M, Le-Thi T, . Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30(6):1608–1610
   PubMed Web of Science ®Google Scholar
• . Fehse F, Trautmann M, Holst JJ, . Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005;90(11):5991–5997
   PubMed Web of Science ®Google Scholar
• . Ferdaoussi M, Abdelli S, Yang JY, . Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes. 2008;57(5):1205–1215
   PubMed Web of Science ®Google Scholar
• . Bregenholt S, Møldrup A, Blume N, . The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun. 2005;330(2):577–584
   PubMed Web of Science ®Google Scholar
• . Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206
   PubMed Web of Science ®Google Scholar
• . Pratley RE, Gilbert M. Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud. 2008;5(2):73–94
   PubMedGoogle Scholar
• . Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(5):376–386
   PubMed Web of Science ®Google Scholar
• . Januvia [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2009
   Google Scholar
• . Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with type 2 diabetes. Diabet Med. 2007;24(9):955–961
   PubMed Web of Science ®Google Scholar
• . Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group.Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143(8):559–569
   PubMed Web of Science ®Google Scholar
• . Zinman B, Gerich J, Buse JB, . Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32(7):1224–1230
   PubMed Web of Science ®Google Scholar
• . Buse JB, Rosenstock J, Sesti G, . Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47
   PubMed Web of Science ®Google Scholar
• . Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–2635
   PubMed Web of Science ®Google Scholar
• . Moretto TJ, Milton DR, Ridge TD, . Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008;30(8):1448–1460
   PubMed Web of Science ®Google Scholar
• . Garber A, Henry R, Ratner R, ; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–481
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 010 Group.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31(12):2315–2317
   PubMed Web of Science ®Google Scholar
• . Marre M, Shaw J, Brandle M, Bebakar WM, . Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268–278
   PubMed Web of Science ®Google Scholar
• . Kendall DM, Riddle MC, Rosenstock J, . Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28(5):1083–1091
   PubMed Web of Science ®Google Scholar
• . Russell-Jones D, Vaag A, Schmitz O, . Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52(10):2046–2055
   PubMed Web of Science ®Google Scholar
• . Rodbard HW, Blonde L, Braithwaite SS, . American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13( suppl 1):1–68
   PubMedGoogle Scholar
• . Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther. 2009;31(7):1511–1523
   PubMed Web of Science ®Google Scholar
• . Clinicaltrials.gov. Novo Nordisk. Examination of the effects of liraglutide on the mode of action of insulin detemir. http://www.clinicaltrials.gov/ct2/show/NCT00873223?term=NCT00873223&rank=1, NCT00873223. 2009. Accessed February 17, 2010
   Google Scholar
• . Clinicaltrials.gov. Novo Nordisk. The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes. http://www.clinicaltrials.gov/ct2/show/NCT00856986?term=NCT00856986&rank=1, NCT00856986. 2009. Accessed February 17, 2010
   Google Scholar
• . Clinicaltrials.gov. Amylin Pharmaceuticals. Addition of exenatide to insulin glargine in type 2 diabetes mellitus. http://www.clinicaltrials.gov/ct2/show/NCT00856986?term=NCT00856986&rank=1, NCT00765817 (Clinicaltrials.gov Identifier). 2009. Accessed February 17, 2010
   Google Scholar
• . Drugstore.com. http://www.drugstore.com. Accessed March 22, 2010
   Google Scholar
• . Rhoads GG, Orsini LS, Crown W, Wang S, Getahun D, Zhang Q. Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. J Occup Environ Med. 2005;47(5):447–452
   PubMed Web of Science ®Google Scholar
• . Yu AP, Wu EQ, Birnbaum HG, Emani S, . Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin. 2007;23(9):2157–2169
   PubMed Web of Science ®Google Scholar
• . Minshall ME, Oglesby AK, Wintle ME, Valentine WJ, Roze S, Palmer AJ. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health. 2008;11(1):22–33
   PubMed Web of Science ®Google Scholar